Zacks Investment Research upgraded shares of AnaptysBio, Inc. (NASDAQ:ANAB) from a sell rating to a hold rating in a report published on Monday, July 17th.
According to Zacks, “AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California. “
A number of other equities research analysts have also recently commented on ANAB. JMP Securities reaffirmed an outperform rating and set a $45.00 price objective on shares of AnaptysBio in a research note on Friday, March 31st. Robert W. Baird assumed coverage on shares of AnaptysBio in a research note on Monday, July 10th. They set an outperform rating and a $36.00 price objective on the stock. Credit Suisse Group reaffirmed an outperform rating and set a $34.00 price objective on shares of AnaptysBio in a research note on Tuesday, April 18th. Stifel Nicolaus raised their price objective on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a buy rating in a research note on Tuesday, May 2nd. Finally, Wedbush dropped their price objective on shares of AnaptysBio from $33.00 to $28.00 and set an outperform rating on the stock in a research note on Wednesday, March 29th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $35.60.
AnaptysBio (NASDAQ ANAB) traded up 2.37% during trading on Monday, hitting $21.99. 290,444 shares of the company’s stock were exchanged. AnaptysBio has a 12-month low of $15.17 and a 12-month high of $30.71. The firm’s market cap is $445.72 million. The company’s 50-day moving average price is $24.81 and its 200 day moving average price is $24.47.
AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.29. The business had revenue of $7 million for the quarter, compared to analysts’ expectations of $3.45 million. Equities analysts forecast that AnaptysBio will post ($2.48) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/08/12/anaptysbio-inc-anab-stock-rating-upgraded-by-zacks-investment-research-updated-updated-updated.html.
In related news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of AnaptysBio stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Holdings A/S Novo sold 491,294 shares of AnaptysBio stock in a transaction on Monday, August 7th. The shares were sold at an average price of $21.12, for a total transaction of $10,376,129.28. Following the completion of the sale, the insider now directly owns 2,952,527 shares in the company, valued at approximately $62,357,370.24. The disclosure for this sale can be found here. Insiders sold a total of 599,040 shares of company stock worth $12,926,210 in the last three months.
Large investors have recently added to or reduced their stakes in the stock. Frazier Management LLC bought a new stake in AnaptysBio during the first quarter worth about $102,354,000. Perceptive Advisors LLC bought a new stake in AnaptysBio during the first quarter worth about $24,474,000. Hamilton Lane Advisors LLC bought a new stake in AnaptysBio during the first quarter worth about $11,213,000. Artal Group S.A. boosted its stake in AnaptysBio by 459.4% in the second quarter. Artal Group S.A. now owns 250,000 shares of the biotechnology company’s stock worth $5,983,000 after buying an additional 205,310 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new stake in AnaptysBio during the first quarter worth about $6,924,000. 72.79% of the stock is currently owned by hedge funds and other institutional investors.
AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.